The neurotoxicity of tissue plasminogen activator?

Journal of Cerebral Blood Flow and Metabolism

Volumn 24, Issue 9, 2004, Pages 945-963

  Kaur, Jaspreet ^a   Zhao, Zonghang ^a   Klein, Gary M ^a   Lo, Eng H ^b   Buchan, Alastair M ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Acute ischemic stroke (AIS); Cerebral hemorrhage Reperfusion; Cerebral ischemia; Neurotoxicity; Tissue plasminogen activator (tPA)

Indexed keywords

[1,2,3,4 TETRAHYDRO 7 (1H IMIDAZOL 1 YL) 6 NITRO 2,3 DIOXO 1 QUINOXALINYL]ACETIC ACID; ABCIXIMAB; AMPA RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; ATENOLOL; BATIMASTAT; CALCIUM ION; CITICOLINE; CLOPIDOGREL; DISUFENTON SODIUM; DIZOCILPINE; DUTEPLASE; EBSELEN; ELIPRODIL; FIBRINOGEN RECEPTOR ANTAGONIST; GELATINASE B; HYDRALAZINE; LACTACYSTIN BETA LACTONE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MATRIX METALLOPROTEINASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NIMODIPINE; PROTEASOME INHIBITOR; THROMBIN INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TRAXOPRODIL; UK 279276; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE DISEASE; ANIMAL CELL; ANIMAL MODEL; BLOOD BRAIN BARRIER; BLOOD CLOT LYSIS; BRAIN BLOOD VESSEL; BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; BRAIN INJURY; BRAIN ISCHEMIA; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; DRUG EFFECT; HUMAN; HYPERTENSION; HYPOTHERMIA; KNOCKOUT MOUSE; MAGNETIC RESONANCE ANGIOGRAPHY; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NERVE CELL CULTURE; NEUROIMAGING; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; SEIZURE; SIGNAL TRANSDUCTION; STROKE; TREATMENT OUTCOME;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CEREBROVASCULAR ACCIDENT; EXTRACELLULAR SPACE; HUMANS; NEUROPROTECTIVE AGENTS; PLASMIN; TISSUE PLASMINOGEN ACTIVATOR;

EID: 4544316926     PISSN: 0271678X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.WCB.0000137868.50767.E8     Document Type: Review

References (198)

1. Adams HP, Brott TG, Furlan AJ, Gomez CT, Grotta J, Helgason CM, Kwiatkowski T, Lyden PD, Marler JR, Tomer J, Feinberg W, Mayberg M, Thies W (1996) Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. Stroke 27:1711-1718
2. Ahn MY, Zhang ZG, Zhang L, Chopp M (1999) The effect of age on expression of endogenous plasminogen activators after focal cerebral ischemia in mice. Brain Res 833:112-116
3. Akassoglou K, Kombrinck KW, Degen JL, Strickland S (2000) Tissue plasminogen activator-mediated fibrinolysis protects against axonal degeneration and demyelination after sciatic nerve injury. J Cell Biol 149:1157-1166
4. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA (2000) Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 283:1145-1150
5. Alexandrov AV, Demchuk AM, Burgin WS, Robinson DJ, Grotta JC; CLOTBUST Investigators (2004) Ultrasound-enhanced thrombolysis for acute ischemic stroke: phase 1. Findings of the CLOTBUST trial. J Neuroimaging 14:113-117
6. Alkon DL, Nelson TJ, Zhao W, Cavallaro S (1998) Time domains of neuronal Ca2+ signaling and associative memory: steps through a calexcitin, ryanodine receptor, K+ channel cascade. Trends Neurosci 21:529-537
7. Andersen M, Overgaard K, Meden P, Boysen G, Choi SC (1999) Effects of citicoline combined with thrombolytic therapy in a rat embolic stroke model. Stroke 30:1464-1471
8. Aoki T, Sumii T, Mori T, Wang X, Lo EH (2002) Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats. Stroke 33:271-277
9. Armstrong PW, Wagner G, Goodman SG, Van de Werf F, Granger C, Wallentin L, Fu Y. ASSENT 3 Investigators (2003) ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction. Eur Heart J 24:1515-1522
10. Aronowski J, Strong R, Shirzadi A, Grotta JC (2003) Ethanol plus caffeine (caffeinol) for treatment of ischemic stroke: preclinical experience. Stroke 34:1246-1251
11. Asahi M, Asahi K, Jung JC, del Zoppo GJ, Fini ME, Lo EH (2000a) Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 20:1681-1689
12. Asahi M, Asahi K, Wang X, Lo EH (2000b) Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats. J Cereb Blood Flow Metab 20:452-457
13. Asahi M, Wang X, Mori T, Sumii T, June J, Moshowitz MA, Fini ME, Lo EH (2001) Effects of matrix metalloproteinase 9 gene knockout on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 21:7724-7732
14. Asahi M, Rammohan R, Sumii T, Wang X, Pauw RJ, Weissig V, Torchilin VP, Lo EH (2003) Antiactin-targeted immunoliposomes ameliorate tissue plasminogen activator-induced hemorrhage after focal embolic stroke. J Cereb Blood Flow Metab 23:895-899
15. Backstrom JR, Lim GP, Cullen MJ, Tokes ZA (1996) Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40). J Neurosci 16:7910-7919
16. Bacskai BJ, Xia MQ, Strickland DK, Rebeck GW, Hyman BT (2000) The endocytic receptor protein LRP also mediates neuronal calcium signaling via N-methyl-D-aspartate receptors. Proc Natl Acad Sci U.S.A. 97:11551-11556
17. Baranes D, Lopez-Garcia JC, Chen M, Bailey CH, Kandel ER (1996) Reconstitution of the hippocampal mossy fiber and associational-commissural pathways in a novel dissociated cell culture system. Proc Natl Acad Sci U.S.A. 93:4706-4711
18. Baranes D, Lederfein D, Huang YY, Chen M, Bailey CH, Kandel ER (1998)Tissue plasminogen activator contributes to the late phase of LTP and to synaptic growth in the hippocampal mossy fiber pathway. Neuron 21:813-825
19. Barber PA, Demchuk AM, Zhang J, Buchan AM (2000) Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Program Early CT Score. Lancet 355:1670-1674. Erratum in: Lancet 2000:355:2170
20. Barber PA, Demchuk AM, Zhang J, Buchan AM (2000) Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Program Early CT Score. Lancet 355:1670-1674. Erratum in: Lancet 2000:355:2170
21. Barmina OY, Walling HW, Fiacco GJ, Freije JM, López-Otín C, Jeffrey JJ, Partridge NC (1999) Collagenase-3 binds to a specific receptor and requires the low density lipoprotein receptor-related protein for internalization. J Biol Chem 274:30087-30093
22. Beck KF, Eberhardt W, Frank S, Huwiler A, Messmer UK, Muhl H, Pfeilschifter J (1999) Inducible NO synthase: Role in cellular signalling. J Exp Biol 202:645-653
23. Bednar MM, Gross CE, Howard DB, Russell SR, Ellenberger C (2001) The effect of vasodilators on aspirin-induced antagonism of t-PA thrombolysis. Neurol Res 23:745-750
24. Benveniste H, Drejer J, Schousboe A, Djemer NH (1984) Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem 43:1369-1374
25. Bignami A, Cella G, Chi NH (1982) Plasminogen activators in rat neural tissues during development and in Wallerian degeneration. Acta Neuropathol (Berl) 58:224-228
26. Bondy SC (1995) The relation of oxidative stress and hyperexcitation to neurological disease. Proc Soc Exp Biol Med 208:337-345
27. Brinker G, Pillenkamp F, Hossman KA (1999) Brain hemorrhage after rt-PA treatment of embolic stroke in spontaneously hypertensive rats. Neuroreport 10:1943-1946
28. Buchan AM, Slivka A, Xue D (1992) The effect of the NMDA receptor antagonist MK-801 on cerebral blood flow and infarct volume in experimental focal stroke. Brain Res 574:171-177
29. Buchan AM, Barber PA, Newcommon N, Karbalai HG, Demchuk AM, Hoyte KM, Klein GM, Feasby TE (2000) Effectiveness of t-PA in acute ischemic stroke: outcome relates to appropriateness. Neurology 54:679-684
30. Buchan AM, Warren DT (2002) tPA toxicity in experimental cerebral ischemia: mechanisms and clinical implications. In: Pharmacology of cerebral ischemia (Krieglstein J, Klumpp S, eds). 193-199
31. Bugge TH, Flick MJ, Daugherty CC, Degen JL (1995) Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 9:794-807
32. Butcher K, Parsons M, Davis S, Donnan G (2003) PW1/DW1 Mismatch: better definition required. Stroke 34:e215-e216
33. Calabresi P, Napolitano M, Centonze D, Marfia GA, Gubellini P, Teule MA, Berretta N, Bernardi G, Frati L, Tolu M, Gulino A (2000) Tissue plasminogen activator controls multiple forms of synaptic plasticity and memory. Eur J Neurosci 12:1002-1012
34. Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De Vos R, van den Oord JJ, Collen D, Mulligan RC (1994) Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368:419-424
35. Carroll PM, Tsirka SE, Richards WG, Frohman MA, Strickland S (1994) The mouse tissue plasminogen activator gene 5′ flanking region directs appropriate expression in development and a seizure-enhanced response in the CNS. Development 120:3173-3183
36. Carter LP, Guthkelch AN, Orozco J, Temeltas O (1992) Influence of tissue plasminogen activator and heparin on cerebral ischemia in a rabbit model. Stroke 23:883-888
37. Chan PH (1996) Role of oxidants in ischemic brain damage. Stroke 27:1124-1130
38. Chan PH (2001) Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab 21:2-14.
39. Chapman DF, Lydeu P, Lapchak PA, Nunez S, Thibodeaux H, Zivin J (2001) Comparison of TNK with wild-type tissue plasminogen activator in a rabbit embolic stroke model. Stroke 32:748-752
40. Chen ZL, Strickland S (1997) Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell 91:917-925
41. Chen ZL, Yoshida S, Kalo K, Momota Y, Suzuki J, Tanaka T, Ito J, Nishino H, Aimoto S, Kiyama H (1995) Expression and activity-dependent changes of a novel limbic-serine protease gene in the hippocampus. J Neurosci 15:5088-5097
42. Chiu D, Krieger D, Villar-Cordova C, Kasner SE, Morgenstern LB, Bratina PL, Yatsu FM, Grotta JC (1998) Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. Stroke 29:18-22
43. Chopp M, Zhang RL, Zhang ZG, Jiang Q (1999) The clot thickens- thrombolysis and combination therapies. Acta Neurochir Suppl (Wien) 73:67-71
44. Clark AW, Krekoski CA, Bou SS, Chapman KR, Edwards DR (1997) Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett 238:53-56
45. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S (1999) Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 282:2019-2026
46. Collen D, Stassen JM, Yasuda T, Refino C, Paoni N, Keyt B, Roskams T, Guerrero JL, Lijnen HR, Gold HK (1994) Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog. Thromb Haemost 72:98-104
47. Davies BJ, Pickard BS, Steel M, Morris RG, Lathe R (1998) Serine proteases in rodent hippocampus. J Biol Chem 273:23004-23011
48. del Zoppo GJ (1998) tPA: a neuron buster, too? Nat Med 4:148-150.
49. Donnan DG, Davis SM, Chambers BR, Gates PC, Hankey GJ, McNeil JJ, Rosen D, Stewart-Wynne EG, Tuck RR (1995) Trials of streptokinase in severe acute ischemic stroke. Lancet 345:578-579
50. Eberhardt W, Beck KF, Pfeilschifter J (2002) Cytokine-induced expression of tPA is differentially modulated by NO and ROS in rat mesangial cells. Kidney Int 61:20-30
51. Fernandez-Monreal M, Lopez-Atalaya JP, Benchenane K, Leveille F, Cacquevel M, Plawinski L, MacKenzie ET, Bu G, Buisson A, Vivien D (2004) Is tissue-type plasminogen activator a neuromodulator? Mol Cell Neurosci 25:594-601
52. Flavin MP, Zhao G, Ho LT (2000) Microglial tissue plasminogen activator triggers apoptosis in vitro. Glia 29:347-354
53. Frey U, Muller M, Kuhl D (1996) A different form of long-lasting potentiation revealed in tissue plasminogen activator mutant mice. J Neurosci 16:2057-2063
54. Friedman GC, Seeds NW (1995) Tissue plasminogen activator mRNA expression in granule neurons coincides with their migration in the developing cerebellum. J Comp Neurol 360:658-670
55. Gautier S, Petrault O, Gele P, Laprais M, Bastide M, Bauters A, Deplanque D, Jude B, Caron J, Bordet R (2003) Involvement of thrombolysis in recombinant tissue plasminogen activator-induced cerebral hemorrhages and effect on infarct volume and postischemic endothelial function. Stroke 34:2975-29799
56. Geschwend TP, Krueger SR, Kozlov SV, Wolfer DP, Sonderegger P (1997) Neurotrypsin, a novel multidomain serine protease expressed in the nervous system. Mol Cell Neurosci 9:207-219
57. Gingrich MB, Junge CE, Lyuboslavsky P, Traynelis SF (2000) Potentiation of NMDA receptor function by the serine protease thrombin. J Neurosci 20:4582-4595
58. Gingrich MB, Traynelis SF (2000) Serine proteases and brain damage-is there a link? Trends Neurosci 23:399-407
59. Ginsberg MD (1999) On ischemic brain injury in genetically altered mice. Arterioscler Thromb Vasc Biol 19:2581-2583.
60. Graham SH, Chen J (2001) Programmed cell death in cerebral ischemia. J Cereb Blood Flow Metab 21:99-109
61. Grond M, Stenzel C, Schmulling S, Rudolf J, Neveling M, Lechleuthner A, Schneweis S, Heiss WD (1998) Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke 29:1544-1549
62. Gualandris A, Jones TE, Strickland S, Tsirka SE (1996) Membrane depolarization induces calcium-dependent secretion of tissue plasminogen activator. J Neurosci 16:2220-2225
63. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P (1998) Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 352:1245-1251
64. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S; ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. (2004) Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363:768-774
65. Hahn-Dantona E, Ruiz JF, Bornstein P, Strickland DK (2001) The low density lipoprotein receptor-related protein modulates levels of matrix metalloproteinase 9 (MMP-9) by mediating its cellular catabolism. J Biol Chem 276:-15498-15503
66. Hamann GF, Okada Y, Fitridge R, del Zoppo GJ (1995) Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion. Stroke 26:2120-2126
67. Hamann GF, Okada Y, del Zoppo GJ (1996) Hemorrhagic transformation and microvascular integrity during focal cerebral ischemia-reperfusion. J Cereb Blood Flow Metab 16:1373-1378
68. Heo JH, Lucero J, Abumiya T, Koizol JA, Copeland BR, del Zoppo GJ (1999) Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab 19:624-633
69. Herz J (2003) LRP, a bright beacon at the blood-brain barrier. J Clin Invest 112:1483-1485
70. Herz J, Strickland DK (2001) LRP: a multifunctional scavenger and signaling receptor. J Clin Invest 108:779-784
71. Hill MD, Barber PA, Demchuk AM, Sevick RJ, Newcommon NJ, Green T, Buchan AM (2000) Building a "brain attack" team to administer thrombolytic therapy for acute ischemic stroke. CMAJ 162:1589-1593
72. Hill MD, Buchan AM (2001) Methodology for the Canadian Activase for Stroke Effectiveness Study (CASES). CASES Investigators. Can J Neurol Sci 28:232-238 Erratum in: Can J Neurol Sci (2002) 29:103
73. Hill MD, Buchan AM (2001) Methodology for the Canadian Activase for Stroke Effectiveness Study (CASES). CASES Investigators. Can J Neurol Sci 28:232-238 Erratum in: Can J Neurol Sci (2002) 29:103
74. Hill MD, Barber PA, Demchuk AM, Newcommon NJ, Cole-Haskayne A, Ryckborst K, Sopher L, Button A, Hu W, Hudon ME, Morrish W, Frayne R, Sevick RJ, Buchan AM (2002) Acute intravenous-intra-arterial revascularization therapy for severe ischemic stroke. Stroke 33:279-282
75. Hill MD, Rowley HA, Adler F, Eliasziw M, Furlan A, Higashida RT, Wechsler LR, Roberts HC, Dillon WP, Fischbein NJ, Firszt CM, Schulz GA, Buchan AM: PROACT-II Investigators. (2003) Selection of acute ischemic stroke patients for intra-arterial thrombolysis with pro-urokinase by using ASPECTS. Stroke 34:1925-3191
76. Huffman KB, Larson J, Bahr BA, Lynch G (1998) Activation of NMDA receptors stimulates extracellular proteolysis of cell adhesion molecules in hippocampus. Brain Res 811:152-155
77. Huang YY, Bach ME, Lipp HP, Zhuo M, Wolfer DP, Hawkins RD, Schoonjans L, Kandel ER, Godfraind JM, Mulligan R, Collen D, Carmeliet P (1996) Mice lacking the gene encoding tissue-type plasminogen activator show a selective interference with late-phase long-term potentiation in both Schaffer collateral and mossy fiber pathways. Proc Natl Acad Sci U.S.A. 93:8699-8704
78. Huang Z, Huang P, Panahian N, Dalkara T, Fishman MC, Moskowitz MA (1994) Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science 265:1883-1885
79. Huang ZG, Xue D, Preston E, Karbalai H, Buchan AM (1999) Biphasic opening of the blood-brain barrier following transient focal ischemia: effects of hypothermia. Can J Neurol Sci 26:298-304
80. IMS Study Investigators, The (2004) Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke 35:904-911
81. Junge CE, Sugawara T, Mannaioni G, Alagarsamy S, Conn PJ, Brat DJ, Chan PH, Traynelis SF (2003) The contribution of protease-activated receptor 1 to neuronal damage caused by transient focal cerebral ischemia. Proc Natl Acad Sci U.S.A. 100:13019-13024
82. Kancha RK, Stearns ME, Hussain MM (1994) Decreased expression of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor in invasive cell clones derived from human prostate and breast tumor cells. Oncol Res 6:365-372
83. Kang DE, Saitoh T, Chen X, Xia Y, Masliah E, Hansen LA, Thomas RG, Thal LJ, Katzman R (1997) Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease. Neurology 49:56-61
84. Kano T, Katayama Y, Tejima E, Lo EH (2000) Hemorrhagic transformation after fibrinolytic therapy with tissue plasminogen activator in a rat thromboembolic model of stroke. Brain Res 854:245-248
85. Katzan IL, Furlan AJ, Lloyd LE, Frank JI, Harper DL, Hinchey JA, Hammel JP, Qu A, Sila CA (2000) Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 283:1151-1158
86. Kilic E, Bahr M, Hermann DM (2001) Effects of recombinant tissue plasminogen activator after intraluminal thread occlusion in mice: role of hemodynamic alterations. Stroke 32:2641-2647
87. Klein GM, Li H, Sun P, Buchan AM (1999) Tissue plasminogen activator does not increase neuronal damage in rat models of global and focal ischemia. Neurology 52:1381-1384
88. Klein G, Barber PA, Warren DT, Buchan AM (2002) Nitric oxide induced by L-arginine present in exogenous t-PA may mediate neurotoxicity in animal models of permanent cerebral ischemia [abstract]. Neurology 58(Suppl 3):A366
89. Krystosek A, Seeds NW (1984) Peripheral neurons and Schwann cells secrete plasminogen activator. J Cell Biol 98:773-776
90. Kuroiwa T, Ting P, Klatzo I (1985) The biphasic opening of the blood-brain barrier to proteins following temporary middle cerebral artery occlusion. Acta Neuropathol 68:122-129
91. Lambert JC, Wavrant-De Vrieze F, Amouyel P, Chartier-Harlin MC (1998) Association at LRP gene locus with sporadic late-onset Alzheimer's disease. Lancet 351:1787-1788.
92. Lapchak PA, Chapman DF, Zivin JA (2000) Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke 31:3034-3040
93. Lapchak PA, Chapman DF, Zivin JA (2001) Pharmacological effects of the spin trap agents N-t-butyl-phenylnitrone (PBN) and 2,2,6, 6- tetramethylpiperidine-N-oxyl (TEMPO) in a rabbit thromboembolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke 32:147-153
94. Lapchak PA, Araujo DM, Pakola S, Song D, Wei J, Zivin JA (2002a) Microplasmin: a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits. Stroke 33:2279-2284
95. Lapchak PA, Araujo DM, Song D, Wei J, Purdy R, Zivin JA (2002b) Effects of the spin trap agent disodium- [tert-butylimino)-methyl]benzene-1,3- disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit large clot embolic stroke model: combination studies with tissue plasminogen activator. Stroke 33:1665-1670
96. Lapchak PA, Araujo DM, Song D, Wei J, Zivin JA (2002c) Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino) ethyl]benzene-1,3- disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke 33:1411-1415
97. Lapchak PA, Zivin JA (2003) Ebselen, a seleno-organic antioxidant, is neuroprotective after embolic strokes in rabbits: synergism with low-dose tissue plasminogen activator. Stroke 34:2013-2018
98. Lapchak PA, Song D, Wei J, Zivin JA (2004a) Pharmacology of caffeinol in embolized rabbits: clinical rating scores and intracerebral hemorrhage incidence. Exp Neurol In Press, available online April 14, 2004
99. Lapchak PA, Araujo DM, Zivin JA (2004b) Comparison of Tenecteplase with Alteplase on clinical rating scores following small clot embolic strokes in rabbits. Exp Neurol 185:154-159
100. Lee SR, Tsuji K, Lee SR, Lo EH (2004) Role of matrix metalloproteinases in delayed neuronal damage after transient global cerebral ischemia. J Neurosci 24:671-678
101. Lekieffre D, Benavides J, Scatton B, Nowicki JP (1997) Neuroprotection afforded by a combination of eliprodil and a thrombolytic agent, rt-PA, in a rat thromboembolic stroke model. Brain Res 776:88-95
102. Liberatore GT, Samson A, Bladin C, Schleuning WD, Medcalfe R (2003) Vampire bat salivary plasminogen activator (Desmoteplase). A unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 34:537-543
103. Lipton P (1999) Ischemic cell death in brain neurons. Physiol Rev 79:1431-1568
104. Lo EH, Wang X, Cuzner ML (2002) Extracellular proteolysis in brain injury and inflammation: role for plasminogen activators and matrix metalloproteinases. J Neurosci Res 69:1-9
105. Lo EH, Dalkara T, Moskowitz MA (2003) Mechanisms, challenges and opportunities in Stroke. Nature Rev Neurosci 4:399-415
106. Lo EH, Broderick JP, Moskowitz MA (2004) Tissue plasminogen activator and proteolysis in the neurovascular unit. Stroke 35:354-356
107. Lochner JE, Kingma M, Kuhn S, Meliza CD, Cutler B, Scalettar BA (1998) Real-time imaging of the axonal transport of granules containing a tissue plasminogen activator/green fluorescent protein hybrid. Mol Biol Cell 9:2463-2476
108. Lu W, Tsirka SE (2002) Partial rescue of neural apoptosis in the Lurcher mutant mouse through elimination of tissue plasminogen activator. Development 129:2043-2050
109. Madani R, Hulo S, Toni N, Madani H, Steimer T, Muller D, Vassalli JD (1999) Enhanced hippocampal long-term potentiation and learning by increased neuronal expression of tissue-type plasminogen activator in transgenic mice. EMBO J 18:3007-1302
110. Mutrisian LM (1990) Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 6:121-125
111. Marder VJ, Landskroner K, Novokhatny V, Zimmerman TP, Kong M, Kanouse JJ, Jesmok G (2001) Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit. Thromb Haemost 86:739-745
112. Matys T, Strickland S (2003) Tissue plasminogen activator and NMDA receptor cleavage. Nature Med 9:371-373
113. Meden P, Overgaard K, Sereghy T, Boysen G (1993) Enhancing the efficacy of thrombolysis by AMPA receptor blockade with NBQX in a rat embolic stroke model. J Neurol Sci 119:209-216
114. Meden P, Overgaard K, Pedersen H, Boysen G (1994) Effect of hypothermia and delayed thrombolysis in a rat embolic stroke model. Acta Neurol Scand 90:91-98
115. Meden P, Andersen M, Overgaard K, Rasmussen RS, Boysen G (2002) The effects of early insulin treatment combined with thrombolysis in rat embolic stroke. Neurol Res 24:399-404
116. Meng W, Wang X, Ashahi M, Kano T, Asahi K, Acherman RH, Lo EH (1999) Effects of tissue type plasminogen activator in embolic versus mechanical models of focal cerebral ischemia in rats. J Cereb Blood Flow Metab 19:1316-1321
117. Miller LP, Hsu C (1992) Therapeutic potential for adenosine receptor activation in ischemic injury. J Neurotrama 9:5563-5577
118. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, Quintana M, Alvarez-Sabin J (2003) Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 107:598-603
119. Morris DC, Zhang L, Zhang ZG, Lu M, Berens KL, Brown PM, Chopp M (2001) Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke. Stroke 32:2635-2640
120. Mori T, Wang X, Kline AE, Siao CJ, Dixon CE, Tsirka SE, Lo EH (2001) Reduced cortical injury and edema in tissue plasminogen activator knockout mice after brain trauma. Neuroreport 12:4117-4120
121. Mun-Bryce S, Rosenberg GA (1998) Matrix metalloproteinases in cerebrovascular disease. J Cereb Blood Flow Metab 18:1163-1172
122. Murphy G, Atkinson S, Ward R, Gavrilovic J, Reynolds JJ (1992) The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann N Y Acad Sci 667:1-12
123. Multicenter Acute Stroke Trial - Italy (MAST-1) Group (1995) Randomised controlled trial of streptokinase, aspirin and combination of both in treatment of acute ischemic stroke. Lancet 346:1509-1514
124. Multicenter Acute Stroke Trial (MAST) - Europe Study Group (1996) Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 335:145-150
125. Nagai N, De Mol M, Lijnen HR, Carmeliet P, Collen D (1999a) Role of plasminogen system components in focal cerebral ischemic infarction. Circulation 99:2440-2444
126. Nagai N, Valinthout D, Collen M (1999b) Comparative effects of tissue plasminogen activator, streptokinase, staphylokinase on cerebral ischemia infarction and pulmonary clot lysis in hamster models. Circulation 100:2541-2546
127. Nagai N, Yamamoto S, Tsuboi T, Ihara H, Urano T, Takada Y, Terakawa S, Takada A (2001) Tissue type plasminogen activator is involved in the process of neuronal death by oxygen-glucose deprivation. J Cereb Blood Flow Metab 21:631-634
128. Nagai N, Zhao B-Q, Suzuki Y, Ihara H, Urano T, Umemura K (2002) Tissue-type plasminogen activator has paradoxical roles in focal cerebral Ischemic injury by thrombotic middle cerebral artery occlusion with mild or severe photochemical damage in mice. J Cereb Blood Flow Metab 22:648-651
129. Nagai N, Demarsin E, Van Hoef B, Wouters S, Cingolani D, Laroche Y, Collen D (2003) Recombinant human microplasmin: production and potential therapeutic properties. J Thromb Haemost 1:307-313
130. Nagase H (1997) Activation mechanisms of matrix metalloproteinases. Biol Chem 378:151-160
131. Nagase H, Woessner JF Jr (1999) Matrix metalloproteinases. J Biol Chem 274:21491-21494
132. Nasser T, Akkawi S, Shina A, Haj-Yehia A, Bdeir K, Tarshis M, Heyman SN, Higazi AA (2004) In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone. Blood 103:897-902
133. National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group (1995) Tissue-plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581-1587
134. Neuhoff H, Roeper J, Schweizer M (1999) Activity-dependent formation of perforated synapses in cultured hippocampal neurons. Eur J Neurosci 11:4241-4250
135. Nicole O, Docagne F, Ali C, Margaill I, Carmeliet P, MacKenzie ET, Vivien D, Buisson A (2001) The proteolylic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nature Med 7:59-64
136. Nishibori M, Ohtsuka A, Kawabata M, Nakaya N, Murakami T, Saeki K (1995) A novel serpin-like protein, B-43, exists in both neurons and astrocytes: an immunohistochemical study in the parietal region of the bovine brain. Neurosci Lett 200:125-128
137. Novokhatny VV, Jesmok GJ, Landskroner KA, Marder VJ, Zimmerman TP (2004) Locally delivered plasmin: why should it be superior to plasminogen activators for direct thrombolysis? Trends Pharmacol Sci 25:72-75
138. Pagenstecher A, Stalder AK, Kincaid CL, Shapiro SD, Campbell IL (1998) Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states. Am J Pathol 152:729-741
139. Farmer RJ, Mahata M, Mahata S, Sebald MT, O'Connor DT, Miles LA (1997) Tissue plasminogen activator (t-PA) is targeted to the regulated secretory pathway. Catecholamine storage vesicles as a reservoir for the rapid release of t-PA. J Biol Chem 272:1976-1982
140. Parry MA, Zhang XC, Bode I (2000) Molecular mechanisms of plasminogen activation: bacterial cofactors provide clues. Trends Biochem Sci 2000 25:53-59
141. Pawlak R, Strickland S (2002) Tissue plasminogen activator and seizures: a clot-buster's secret life. J Clin Invest 109:1529-1531
142. Piriyawat P, Labiche LA, Burgin WS, Aronowski JA, Grotta JC (2003) Pilot dose-escalation study of caffeine plus ethanol (caffeinol) in acute ischmemic stroke. Stroke 34:1242-1245
143. Qian Z, Gilbert ME, Colicos MA, Kandel ER, Kuhl D (1993) Tissue-plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation. Nature 361:453-457
144. Qureshi AI, Pande RU, Kim SH, Hanel RA, Kirmani JF, Yahia AM (2002) Third generation thrombolytics for the treatment of ischemic stroke. Curr Opin Investig Drugs 3:1729-1732
145. Rivera S, Ogier C, Jourquin J, Timsit S, Szklarczyk AW, Miller K, Gearing AJ, Kaczmarek L, Khrestchatisky M (2002) Gelatinase B and TIMP-1 are regulated in a cell- and time-dependent manner in association with neuronal death and glial reactivity after global forebrain ischemia. Eur J Neurosci 15:19-32
146. Rogove A, Siao C-J, Keyt B, Strickland S, Tsirka S (1999) Activation of microglia reveals a non-proteolytic cytokine function for tissue plasminogen activator in the central nervous system. J Cell Sci 112:4007-4016
147. Rosenberg GA, Estrada EY, Dencoff JE (1998) Matrix metalloproteinases and TlMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 29:2189-2195
148. Rudolphi KA, Keil M, Fastborn J, Fredholm BB (1989) Ischemic damage in gerbil hippocampus is reduced following upregulation of adenosine (A1) receptors by caffeine treatment. Neurosci Lett 103:275-280
149. Salles FJ, Schechter N, Strickland S (1990) A plasminogen activator is induced during goldfish optic nerve regeneration. EMBO J 9:2471-2477
150. Salles FJ, Strickland S (2002) Localization and regulation of the tissue plasminogen activator-plasmin system in the hippocampus. J Neurosci 22:2125-2134
151. Sappino AP, Madani R, Huarte J, Belin D, Kiss JZ, Wohlwend A, Vassalli JD (1993) Extracellular proteolysis in the adult murine brain. J Clin Invest 92:679-685
152. Scarisbrick IA, Isackson PJ, Ciric B, Windebank AJ, Rodriguez M (2001) MSP, a trypsin-like serine protease, is abundantly expressed in the human nervous system. J Comp Neurol 431:347-361
153. Seeds NW, Williams BL, Bickford PC (1995) Tissue plasminogen activator induction in Purkinje neurons after cerebellar motor learning. Science 270:1992-1994
154. Seeds NW, Siconolfi LB, Haffke SP (1997) Neuronal extracellular proteases facilitate cell migration, axonal growth, and pathfinding. Cell Tissue Res 290:367-370
155. Seeds NW, Basham ME, Ferguson JE (2003) Absence of tissue plasminogen activator gene or activity impairs mouse cerebellar motor learning. J Neurosci 23:7368-7375
156. Serebruany VL, Malinin AI, Callahan KP, Binbrek A, Van De Werf F, Alexander JH, Granger CB, Gurbel PA (2003) Assessment of the safety and efficacy of a new thrombolytic agent platelet substudy. effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy. Am Heart J 145:636-642
157. Shuaib A, Yang Y, Nakada MT, Li Q, Yang T (2002) Glycoprotein IIb/IIIa antagonist, murine 7E3 F(ab')2, a tissue plasminogen activator in focal ischemia: evaluation of efficacy and risk of hemorrhage with combination therapy. J Cereb Blood Flow Metab 22:215-222
158. Siao CJ, Fernandez SR, Tsirka SE (2003) Cell type-specific roles for tissue plasminogen activator released by neurons or microglia after excitotoxic injury. J Neurosci 23:3234-3242
159. Siao CJ, Tsirka SF (2002) Extracellular proteases and neuronal cell death. Cell Mol Biol 48:151-161
160. Siconolfi LB, Seeds NW (2001) Mice lacking t-PA, u-PA, or plasminogen genes showed delayed functional recovery after sciatic nerve crush. J Neurosci 21:4348-4355
161. Siconolfi LB, Seeds NW (2003) Mice lacking tissue plasminogen activator and urokinase plasminogen activator genes show attenuated matrix metalloproteases activity after sciatic nerve crush. J Neurosci Res 74:430-434.
162. Sumii T, Lo EH (2002) Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 33:831-836
163. Strickland S (2001) Tissue plasminogen activator in nervous system function and dysfunction. Thromb Haemost 86:138-143
164. Suzuki Y, Kano T, Katayama Y, Tejima E, Harada T (2003) Reduction of infarction volume by bolus injection of pamiteplase, a modified tissue plasminogen activator with a longer half-life. Neurol Res 25:477-480
165. Tabrizi P, Wang L, Seeds N, McComb JG, Yamada S, Griffin JH, Carmeliet P, Weiss MH, Zlokovic BV (1999) Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background. Arterioscler Thromb Vasc Biol 19:2801-2806
166. Thomas GR, Thibodeaux H, Errett CJ, Badillo JM, Keyt BA, Refino CJ, Zivin JA, Bennett WF (1994) A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding. Stroke 25:2072-2078
167. Tsirka SE, Gualandris A, Amaral DG, Strickland S (1995) Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 377:340-344
168. Tsirka SE, Rogove AD, Strickland S (1996) Neuronal cell death and tPA. Nature 384:123-124
169. Tsirka SE, Rogove AD, Bugge TH, Degen JL, Strickland S (1997) An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J Neurosci 17:543-552
170. Vanderschueren S, Van Vlaenderen DVM, Collen D (1997) Intravenous thrombolysis with recombinant staphylokinase versus tissue-type plasminogen activator in a rabbit embolic stroke model. Stroke 28:1783-1788
171. Van de Werf F, Barron HV, Armstrong PW, Granger CB, Berioli S, Barbash G, Pehrsson K, Verbeugt FW, Meyer J, Betriu A, Califf RM, Li X, Fox NL: ASSENT-2 Investigators (2001) Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. Eur Heart J 22:2253-2261
172. Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, Lipton SA (1998) Tissue plasminogen activator (t-PA) increases neuronal damage after focal cerebral ischemia in wild-type and t-PA-deficient mice. Nat Med 4:228-231
173. Wang X, Asahi M, Lo EH (1999) Tissue type plasminogen activator amplifies hemoglobin-induced neurotoxocity in rat neuronal cultures. Neurosci Lett 274:79-82
174. Wang X, Jung J, Asahi M, Chwang W, Russo L, Moskowitz MA, Dixon CE, Fini ME, Lo EH (2000) Effects of matrix metalloproteinase-9 gene knock-out on morphological and motor outcomes after traumatic brain injury. J Neurosci 20:7037-7042
175. Wang X, Mori T, Jung JC, Fini ME, Lo EH (2002) Secretion of matrix metalloproteinase-2 and -9 after mechanical trauma injury in rat cortical cultures and involvement of MAP kinase. J Neurotrauma 19:615-625
176. Wang X, Lee SR, Arai K, Lee SR, Tsuji K, Rebeck GW, Lo EH (2003) Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 9:1313-1317
177. Wardlaw JM, del Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute ischaemic stroke (Cochrane Review). In: The Cochrane Library, Issue 3, 2004. Chichester, UK: John Wiley & Sons. Ltd. (3):AB000213
178. Warren DT, Klein G, Eliasziw M, Buchan AM (2003) Neurotoxic effects of t-PA in a rat model of permanent focal ischemia [abstract]. Neurology 60(Suppl 1):A65
179. Werner RG (2001) Improving natural principles with genetic engineering: TNK-tissue plasminogen activator. Arzneimittelforschung 51:516-520
180. Wu YP, Siao CJ, Lu W, Sung TC, Frohman MA, Miley P, Bugge TH, Dogen JL, Levine JM, Margolis RU, Tsirka SE (2000) The tissue plasminogen activator (tPA)/plasmin extracellular proteolytic system regulates seizure-induced hippocampal mossy fiber outgrowth through a proteoglycan substrate. J Cell Biol 148:1295-1304
181. Yang Y, Li Q, Yang T, Hussain M, Shuaib A (2003) Reduced brain infarct volume and improved neurological outcome by inhibition of the NR2B subunit of NMDA receptors by using CP101, 606-27 alone and in combination with rt-PA in a thromboembolic stroke model in rats. J Neurosurg 98:397-403
182. Yang Z, Strickland DK, Bornstein P (2000) Extracellular MMP2 levels are regulated by the LRP scavenger receptor and thrombospondin 2. J Biol Chem 276:8403-8408
183. Yenari MA, Palmer JT, Bracci PM, Steinberg GK (1995) Thrombolysis with tissue plasminogen activator (tPA) is temperature dependent. Thromb Res 77:475-481
184. Yepes M, Sandkvist M, Wong MK, Coleman TA, Smith E, Cohan SL, Lawrence DA (2000) Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood 96:569-576
185. Yepes M, Sandkvist M, Coleman TA, Moore E, Wu JY, Mitola D, Bugge TH, Lawrence DA (2002) Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen- independent. J Clin Invest 109:1571-1578
186. Yepes M, Sandkvist M, Moore EG, Bugge TH, Strickland DK, Lawrence DA (2003) Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest 112:1533-1540
187. Yong VW, Krekoski CA, Forsyth PA, Bell R, Edwards DR (1998) Matrix metalloproteinases and diseases of the CNS. Trends Neurosci 21:75-80
188. Yong VW, Power C, Forsyth P, Edwards DR (2001) Metalloproteinases in biology and pathology of the nervous system. Nature Rev Neurosci 2:502-511
189. Zalewska T, Ziemka-Nalecz M, Sarnowska A, Domanska-Janik K (2003) Transient forebrain ischemia modulates signal transduction from extracellular matrix in gerbil hippocampus. Brain Res 977:62-69
190. Zhang L, Zhang ZG, Zhang RL, Lu M, Adams J, Elliott PJ, Chopp M (2001) Postischemic (6-hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia. Stroke 32:2926-2931
191. Zhang RL, Chopp M, Zhang ZG, Divine G (1998) Early (1 h) administration of tissue plasminogen activator reduces infarct volume without increasing hemorrhagic transformation after focal cerebral embolization in rats. J Neurol Sci 160:1-8
192. Zhang RL, Zhang ZG, Chopp M, Zivin JA (1999) Thrombolysis with tissue plasminogen activator alters adhesion molecule expression in the ischemic rat brain. Stroke 30:624-629
193. Zhang RL, Zhang L, Jiang Q, Zhang ZG, Goussev A, Chopp M (2000) Postischemic intracarotid treatment with TNK-tPA reduces infarct volume and improves neurological deficits in embolic stroke in the unanesthetized rat. Brain Res 878:64-71
194. Zhang L, Zhang ZG, Zhang RL, Lu M, Krams M, Chopp M (2003) Effects of a selective CD11b/CD18 antagonist and recombinant human tissue plasminogen activator treatment alone and in combination in a rat embolic model of stroke. Stroke 34:1790-1795
195. Zhang Z, Zhang L, Yepes M, Jiang Q, Li Q, Arniego P, Coleman TA, Lawrence DA, Chopp M (2002) Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke. Circulation 106:740-745
196. Zhao BQ, Ikeda Y, Ihara H, Urano T, Fan W, Mikawa S, Suzuki Y, Kondo K, Sato K, Nagai N, Umemura K (2004) Essential role of endogenous tissue plasminogen activator through matrix metalloproteinase 9 induction and expression on heparin-produced cerebral hemorrhage after cerebral ischemia in mice. Blood 103:2610-2616
197. Zhuo M, Holtzman DM, Li Y, Osaka H, DeMaro J, Jacquin M, Bu G (2000) Role of tissue plasminogen activator receptor LRP in hippocampal long-term potentiation. J Neurosci 20:542-549
198. Zivin JA, Mazzarella V (1991) Tissue plasminogen activator plus glutamate antagonist improves outcome after embolic stroke. Arch Neurol 48:1235-1238